Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 4200 Marathon Blvd Ste 200 AUSTIN TX 78756-3433 |
Tel: | N/A |
Website: | www.plustherapeutics.com |
IR: | See website |
Key People | ||
Marc H. Hedrick President, Chief Executive Officer, Director | Andrew Sims Chief Financial Officer | Pius Maliakal Vice President - Clinical Operations | Norman Lafrance Chief Medical Officer |
Business Overview |
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company's Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers. |
Financial Overview |
For the fiscal year ended 31 December 2023, Plus Therapeutics Inc (USA) revenues increased from $224K to $4.9M. Net loss decreased 34% to $13.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest Expense decrease of 44% to $395K (expense), Interest Income increase from $147K to $400K (income). |
Employees: | 20 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $12.42M as of Dec 31, 2023 |
Annual revenue (TTM): | $4.91M as of Dec 31, 2023 |
EBITDA (TTM): | -$12.69M as of Dec 31, 2023 |
Net annual income (TTM): | -$13.32M as of Dec 31, 2023 |
Free cash flow (TTM): | -$13.01M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 4,276,082 as of Feb 26, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |